Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949410 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2TACR1 | |
| SCHEMBL948455 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2TACR1 | |
| SCHEMBL949634 | 0.86 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3KCNH2TACR1 | |
| SCHEMBL948515 | 0.86 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3KCNH2TACR1 | |
| SCHEMBL948516 | 0.86 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3KCNH2TACR1 | |
| SCHEMBL948777 | 0.83 | CHRM2 (0.44) | SLC6A4SLC6A2SLC6A3KCNH2CACNA2D1 | |
| SCHEMBL949251 | 0.83 | CHRM2 (0.44) | SLC6A4SLC6A2SLC6A3KCNH2CACNA2D1 | |
| SCHEMBL17440453 | 0.83 | RPLP1 (0.44) | SLC6A4SLC6A2SLC6A3KCNH2CACNA2D1 | |
| SCHEMBL948779 | 0.83 | CHRM2 (0.44) | SLC6A4SLC6A2SLC6A3KCNH2CACNA2D1 | |
| SCHEMBL9428898 | 0.83 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3KCNH2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021569-A1 | Piperidine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER, UNIVERSITE (FR) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021569-A1 | Piperidine compounds, a process for their preparation and pharmaceutical compositions containing them | BDNF, GRIN2C, GRIN2A | SLC6A4 1548/4885SLC6A2 1824/4885SLC6A3 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.